ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 ...
In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...
With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on ...
Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...
Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple ...
StockStory.org on MSN
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback